GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » Price-to-Free-Cash-Flow

Kronos Bio (Kronos Bio) Price-to-Free-Cash-Flow : N/A (As of Apr. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kronos Bio Price-to-Free-Cash-Flow?

As of today (2024-04-30), Kronos Bio's share price is $1.03. Kronos Bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.37. Hence, Kronos Bio's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Kronos Bio's Price-to-Free-Cash-Flow or its related term are showing as below:

KRON's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.61
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Kronos Bio's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.43. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.37.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 22.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -36.20% per year.

During the past 6 years, Kronos Bio's highest 3-Year average Free Cash Flow per Share Growth Rate was 22.20% per year. The lowest was -103.70% per year. And the median was -36.90% per year.


Kronos Bio Price-to-Free-Cash-Flow Historical Data

The historical data trend for Kronos Bio's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kronos Bio Price-to-Free-Cash-Flow Chart

Kronos Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Kronos Bio Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kronos Bio's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Kronos Bio's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kronos Bio's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kronos Bio's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Kronos Bio's Price-to-Free-Cash-Flow falls into.



Kronos Bio Price-to-Free-Cash-Flow Calculation

Kronos Bio's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.03/-1.369
=N/A

Kronos Bio's Share Price of today is $1.03.
Kronos Bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Kronos Bio  (NAS:KRON) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Kronos Bio Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Kronos Bio's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Kronos Bio (Kronos Bio) Business Description

Traded in Other Exchanges
N/A
Address
1300 So. El Camino Real, Suite 300, San Mateo, CA, USA, 94402
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
Executives
Jorge Dimartino officer: Chief Medical Officer & VP C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore officer: Chief Scientific Officer C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz officer: COO & General Counsel 3175 HANOVER STREET, PALO ALTO CA 94304
Norbert W Bischofberger director, 10 percent owner, officer: President & CEO 333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Sandra A. Gardiner officer: Interim CFO CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130

Kronos Bio (Kronos Bio) Headlines

From GuruFocus

Kronos Bio Announces Participation in Upcoming Investor Conferences

By sperokesalga sperokesalga 06-01-2023

Kronos Bio Announces Changes to Board of Directors

By sperokesalga sperokesalga 04-11-2023